干扰素β-1a 对多发性硬化症患者视神经炎复发的影响。

The effect of interferon beta-1a on optic neuritis relapse in patients with multiple sclerosis.

机构信息

Department of Ophthalmology, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, Taiwan.

出版信息

Graefes Arch Clin Exp Ophthalmol. 2010 Feb;248(2):231-5. doi: 10.1007/s00417-009-1207-2. Epub 2009 Oct 6.

DOI:10.1007/s00417-009-1207-2

PMID:19806357

Abstract

BACKGROUND

To evaluate the clinical effect of interferon beta-1a on optic neuritis (ON) relapse in patients with multiple sclerosis (MS) in Taiwan.

METHODS

Data were collected from 23 MS patients with ON at National Taiwan University Hospital between January 1, 1993 and February 1, 2007. Twenty-three MS patients with ON received interferon beta-1a (Rebif) 44 microg via subcutaneous injection three times weekly. All patients received corticosteroids pulse therapy followed by oral prednisolone for acute ON. The annual relapse rate (ARR) of ON in these MS patients before and after the use of interferon beta-1a (Rebif) was the main clinical parameter of outcome in this study.

RESULTS

The ARR of ON was lower in the posttreatment period than in the pretreatment period (P = 0.0068). Thirteen patients (56.5%) had improved final visual acuity (>2 lines), and the other ten patients (43.5%) had stable final visual outcome (-2 lines < X < 2 lines). In addition, no recurrence of ON was noted in 15 patients (65.2%) during the posttreatment period.

CONCLUSIONS

The use of interferon beta-1a 44 microg via subcutaneous injection three times weekly did not increase the ON attacks in MS patients receiving this treatment. In addition, beneficial effects were found with the use of interferon beta-1a on these patients.

摘要

背景

评估干扰素β-1a 在台湾多发性硬化症（MS）患者视神经炎（ON）复发中的临床疗效。

方法

收集 1993 年 1 月 1 日至 2007 年 2 月 1 日期间在国立台湾大学医院就诊的 23 例 MS 合并 ON 患者的数据。23 例 MS 合并 ON 患者接受干扰素β-1a（Rebif）44μg，每周皮下注射 3 次。所有患者均接受皮质类固醇脉冲治疗，随后口服泼尼松龙治疗急性 ON。这些 MS 患者在使用干扰素β-1a（Rebif）前后的视神经炎年复发率（ARR）是本研究的主要临床结局参数。